T. Cooper Woods, Ph.D.

Staff Scientist, Laboratory of Molecular Cardiology, Ochsner Clinic Foundation and
Instructor, Department of Pharmacology
COBRE Junior Investigator
Cardiovascular Center of Excellence
LSUHSC – New Orleans

Mentors:

Guangyu Wu, Ph.D.
Suresh Alahari, Ph.D.
Jack Strong, M.D.

Narrative Biograph:

Dr. Woods received his B.S. degree in Chemistry and Music from the University of the South, and his Ph.D. in Biophysical Sciences from the University of Alabama at Birmingham. He trained in vascular biology under Elazer R. Edelman, M.D., Ph.D. at the Massachusetts Institute of Technology and also under Andrew R. Marks, M.D. at Columbia University Medical Center before starting the Laboratory of Molecular Cardiology at Ochsner Clinic Foundation. The overall goal of this laboratory is to better understand how complicating diseases effect the progression of vascular disease. Additionally, his laboratory works to promote collaborations between the clinicians at Ochsner and the scientists in the Department of Pharmacology & Experimental Therapeutics at LSU Health Sciences - New Orleans, where he also maintains a faculty appointment.

Dr. Woods has published in diverse fields ranging from the basic science of protein folding to oral and nasal drug delivery to his current work examining the effects of diabetes on vascular biology. In 1999, he was awarded the Controlled Release Society’s Outstanding Pharmaceutical Paper Award. His current research is supported both by a CoBRE grant to the Department of Pharmacology from the National Institutes of Health and a Grant-in-Aid from the Greater Southeast Affiliate of the American Heart Association. These projects focus on the role of the mammalian Target of Rapamycin pathway in vascular diseases.

CoBRE Research Summary:

Dr. Wood’s CoBRE project examines the underlying reasons that diabetic patients respond differently to the drug rapamycin. Rapamycin is widely used to prevent closure of stents in the treatment of coronary artery disease. Studies have demonstrated that rapamycin is less effective in treating diabetic patients, which suggests there are important differences by which vascular diseases develop in diabetics versus non-diabetics. Our studies will identify these differences and therefore provide insight into the design of future coronary artery disease therapies that are applicable to growing population of diabetics.

Selected Publications:

Stephanie C. Moss, Daniel Lightell, Jr., Richard Deichmann, and T. Cooper Woods. Sera from Diabetics does not Alter the Effect of mTOR Inhibition on Smooth Muscle Cell Proliferation.  J. Cardiovascular Pharm., 53 (1):86-89, 2009.

Stephanie C. Moss, Michael Bates, Patrick E. Parrino, and T. Cooper Woods. Isolation of Endothelial Cells and Vascular Smooth Muscle Cells from Internal Mammary Artery Tissue.  The Ochsner Journal, 7 (3):133-136, 2007.

Karine Oumouna-Benachour, Chetan P Hans, Yasuhiro Suzuki, Amarjit Naura, Rahul Datta, Souad Belmadani, T. Cooper Woods, and Hamid Boulares, PARP-1 Inhibition Reduces Atherosclerotic Plaque Size and Promotes Factors of Plaque Stability in ApoE-Deficient Mice: Effects on Macrophage Recruitment, NF-kappaB Nuclear Translocation, and Foam Cell Death. Circulation, 115 (18):2442-50, 2007.

Yung-Wei Chi, Christopher J. White, T. Cooper Woods, Corey K. Goldman, Ultrasound velocity criteria for carotid in-stent restenosis. Catheterization and Cardiovascular Interventions, 69(3),p349 – 354, 2006.

T. Cooper Woods and Dan W. Urry.  Controlled Release of Phosphorothioates by Protein-based Polymers. Drug Delivery, 13(4), p. 253-259, 2006.

T. Cooper Woods, Frank Mercogliano, Bin Zhang, and Steven M. Dinh. Response of the Lung to Pulmonary Insulin Dosing in the Rat Model and Effects of Changes in Formulation. Diabetes Technology & Therapeutics, 7(3), p. 516-524, 2005.

T. Cooper Woods, Chad R. Blystone, and Elazer R. Edelman. Activation of EphB2 and its ligands promotes vascular smooth muscle proliferation. J. Biol. Chem., 277, p. 1924-1927, 2002.

Frederick G. P. Welt, T. Cooper Woods, Elazer R. Edelman. Oral heparin prevents neointimal hyperplasia after arterial injury: inhibitory potential depends on type of vascular injury. Circulation. 104(25) p. 3121-4, 2001.

Dan W. Urry, Shao Q. Peng, , Larry C. Hayes, David T. McPherson, Jie Xu, T. Cooper Woods, D. C. Gowda, and Asima Pattanaik Engineering Protein-based Machines to Emulate Key Steps of Metabolism (Biological Energy Conversion). Biotechnology and Bioengineering, 58 (2 and 3) p. 175-190, 1998.

Dan W. Urry, Asima Pattanaik, Jie Xu, T. Cooper Woods, McPherson, D., and Timothy M. Parker. Elastic Protein-based Polymers in Soft Tissue Augmentation and Reconstruction. J. of Biomaterials Science, (9) 1998.